Core Viewpoint - The legal opinion letter from Beijing Jiayuan Law Firm confirms the legality and compliance of the adjustments to the 2022 equity incentive plan and the cancellation of certain unvested restricted stocks for Guangdong Xinjingang Technology Co., Ltd. [1][4][6] Summary by Sections Legal Basis and Investigation - The law firm conducted an investigation into the qualifications for implementing the 2022 equity incentive plan and reviewed relevant documents, ensuring that all materials provided by the company were true, accurate, and complete [2][3]. Approval and Authorization - The necessary procedures for the price adjustment of the 2022 equity incentive plan have been completed, including the approval of relevant proposals at six meetings, with related directors abstaining from voting [3][4]. Adjustment Details - The adjustment of the grant price is based on the company's profit distribution plan, which proposes a cash dividend of RMB 1.00 per 10 shares, leading to an adjusted grant price of approximately RMB 8.325 per share after accounting for the dividend [4][5]. Cancellation of Restricted Stocks - A total of 928,200 shares of restricted stock were canceled due to the failure to meet performance targets and the departure of three incentive recipients, which aligns with the provisions of the 2022 incentive plan [6][7]. Conclusion - The law firm concludes that the actions taken regarding the price adjustment and the cancellation of unvested restricted stocks comply with relevant laws, regulations, and the company's articles of association [7].

Core Viewpoint - The company has announced the cancellation of 928,200 unvested restricted stocks from its 2022 stock incentive plan due to the departure of three original incentive targets and the failure to meet performance assessment requirements for 2024 [4][5][6]. Summary by Sections Approval Procedures for the 2022 Stock Incentive Plan - The company held multiple board and supervisory meetings in October and November 2022 to approve the stock incentive plan and its management methods, with independent opinions provided by the independent directors [1][2][3]. Specifics of the Canceled Restricted Stocks - The cancellation involves 928,200 shares that were granted but not vested, as three original incentive targets left the company and the company did not meet the performance criteria for the second vesting period [4][5][6]. Impact of the Cancellation on the Company - The cancellation of these restricted stocks will not materially affect the company's financial status or operational results, nor will it impact the stability of the management team or the ongoing implementation of the stock incentive plan [5]. Supervisory Board Opinion - The supervisory board has reviewed the situation and agrees with the cancellation, confirming that it complies with relevant laws and regulations without harming shareholder interests [6]. Legal Opinion Conclusion - The stock incentive plan cancellation has received the necessary authorizations and approvals, aligning with the management regulations and the company's articles of association [6].

Summary of Key Points Core Viewpoint The announcement details the achievement of the first vesting conditions for the 2024 restricted stock incentive plan of Hunan YN Energy Battery Materials Co., Ltd, allowing 264 eligible participants to receive a total of 3.549651 million shares, which represents 0.4688% of the company's total share capital. Group 1: Incentive Plan Overview - The incentive plan involves the issuance of restricted stock to eligible participants, with a total of 1,514.506 million shares initially planned, of which 1,238.210 million shares were designated for the first grant [1][2][10] - The vesting price for the restricted stock was adjusted from 17.43 yuan per share to 16.855 yuan per share [9][10] Group 2: Eligible Participants and Share Distribution - A total of 264 individuals are eligible for the first vesting period, with the distribution of shares as follows: - Chairman Tan Xinqiao: 1.21988 million shares - General Manager Zhao Huaqiu: 0.36597 million shares - Other executives and core personnel received the remaining shares [2][12][14] Group 3: Vesting Conditions and Performance Targets - The first vesting period is set from July 3, 2025, to July 2, 2026, with a vesting ratio of 30% for the first grant [12][14] - Performance targets for the first vesting period include a sales growth rate of at least 25% for phosphate cathode materials compared to 2023 [5][12] Group 4: Compliance and Approval - The board of directors and the supervisory board have approved the vesting conditions, confirming that all legal and regulatory requirements have been met [15][18] - The independent financial advisor has also confirmed that the conditions for the first vesting period have been satisfied [18]

Group 1 - The company held its sixth meeting of the fifth supervisory board on June 10, 2025, via telephone and email, which complied with relevant laws and regulations [1] - The supervisory board approved the proposal to cancel 928,200 shares of the second category of restricted stock from the 2022 incentive plan due to three original incentive targets leaving the company and the 2024 performance not meeting the required targets [1][2] - The board agreed to adjust the grant price of the 2022 restricted stock incentive plan to 8.325 yuan per share following the completion of the 2024 annual equity distribution plan [2] Group 2 - The company’s wholly-owned subsidiary, Guangdong Kuanpu Technology Co., Ltd., applied for a comprehensive credit limit from China Merchants Bank, with the company providing guarantees for the application [2][3] - The credit limit will cover various financing activities, including bank acceptance bills and pledged financing, with a term of 12 months [2]

Core Viewpoint - The announcement details the first vesting results of the 2022 restricted stock incentive plan for Sino Medical Technology Co., Ltd, including the number of shares to be listed and the vesting schedule [1][5]. Group 1: Stock Listing and Vesting Details - The stock type for this listing is equity incentive shares, with a total of 2,592,000 shares to be listed for circulation [1][6]. - The listing date for these shares is set for June 23, 2025 [1][6]. - The shares are part of the first vesting results of the third vesting period of the 2022 restricted stock incentive plan [1][5]. Group 2: Decision-Making Process and Disclosure - The decision-making process for the stock vesting involved multiple meetings of the board and supervisory committee, with independent directors providing clear consent [2][4]. - The company publicly disclosed the incentive plan and related documents on the Shanghai Stock Exchange website [3][4]. Group 3: Basic Information on Stock Vesting - A total of 28 individuals are involved in this vesting, with 259,200 shares vested, representing 32% of the total granted stock [6][7]. - The shares are sourced from the company's directed issuance of A-shares to the incentive recipients [6][7]. Group 4: Impact on Financials - The newly vested shares will increase the total share capital from 413,456,000 to 416,048,000 shares, with the new shares accounting for approximately 0.6269% of the total share capital [6][7]. - The vesting of these shares is not expected to have a significant impact on the company's recent financial performance [7].

Core Viewpoint - The company has announced an adjustment to the grant price of the restricted stock incentive plan for 2024, reducing it from 6.00 yuan per share to 5.85 yuan per share due to dividend distributions [4][5]. Group 1: Decision Process and Disclosure - The board of directors and the supervisory board have approved the adjustment of the grant price for the restricted stock incentive plan during their respective meetings [1][3]. - The company has complied with the necessary decision-making procedures and disclosed relevant information as per regulations [1][2]. Group 2: Reasons for Adjustment and Results - The adjustment was necessitated by the implementation of cash dividends of 0.05 yuan and 0.10 yuan per share, leading to a virtual dividend distribution of approximately 0.04939 yuan and 0.09879 yuan per share [4]. - The adjusted grant price formula is P = P0 - V, where P0 is the original grant price and V is the dividend amount [4]. Group 3: Impact of Adjustment - The adjustment of the grant price is in accordance with relevant laws and regulations and will not materially affect the company's financial status or operational results [4]. - The supervisory board has confirmed that the adjustment does not harm the interests of the company or its shareholders [4]. Group 4: Legal Opinion - The legal opinion confirms that the adjustment has received the necessary approvals and complies with the company's incentive plan and relevant regulations [5].

Summary of Key Points Core Viewpoint - The company has implemented a restricted stock incentive plan, distributing a total of 1,186,440 shares to 72 individuals, which represents 0.8947% of the company's total share capital as of the grant date [1]. Group 1: Incentive Plan Distribution - The total number of restricted shares granted to directors, senior management, and core technical personnel is 381,000, accounting for 32.1129% of the total shares granted [1]. - The company has allocated 605,440 shares (51.0300%) to 64 domestic personnel deemed necessary for incentives, while 200,000 shares (16.8572%) are allocated to 2 foreign personnel [1]. - The total number of shares granted under the incentive plan does not exceed 1% of the company's total share capital for any individual recipient and is capped at 20% of the total share capital at the time of the plan's submission for shareholder approval [1]. Group 2: Breakdown of Recipients - Among the directors and senior management, the largest allocation is to Wu Jiangang, who received 200,000 shares, representing 16.8572% of the total shares granted [1]. - The technical backbone received 490,000 shares (41.3000%), while the business backbone received 315,440 shares (26.5871%) [1]. - The total allocation to the technical and business backbones combined is 805,440 shares, which constitutes 67.8871% of the total shares granted [1].

Core Points - The company has conducted a review of the list of incentive recipients for the 2025 restricted stock incentive plan, confirming compliance with relevant laws and regulations [1][2][3] - The incentive plan will grant 1,186,440 shares of restricted stock at a price of 72.81 yuan per share to 72 eligible recipients [3] Summary by Sections - **Eligibility Criteria**: The company outlined conditions under which individuals cannot be included as incentive recipients, including being deemed inappropriate by the stock exchange or regulatory bodies within the last 12 months, and other legal disqualifications [2] - **Approval of Incentive Plan**: The board's compensation and assessment committee has approved the list of recipients and set the grant date for June 20, 2025 [3]

Core Viewpoint - The announcement details the completion of the first vesting period for the 2024 Restricted Stock Incentive Plan, with a total of 642,138 shares being vested to 118 individuals, sourced from shares repurchased from the secondary market [1][6]. Group 1: Stock Vesting Details - The number of shares vested in this period is 642,138 shares, which were repurchased from the secondary market [1]. - The vesting decision followed a series of proposals and approvals from the board and supervisory committee, ensuring compliance with relevant regulations [2][3]. - The total number of individuals receiving shares in this vesting period is 118 [6]. Group 2: Source and Impact on Capital Structure - The shares for this vesting were sourced from the company's repurchased A-shares, meaning there will be no change in the total share capital of the company [7]. - The vesting does not lead to any changes in the controlling shareholder or actual controller of the company [7]. Group 3: Compliance and Verification - The company received a verification report from Yongtuo Accounting Firm confirming the contributions made by the incentive recipients, totaling RMB 15,379,205.10 [6]. - The company has completed the share registration procedures for the vested shares as of June 4, 2025 [6].

Meeting Overview - The third meeting of the Supervisory Board of Hangzhou Anjisi Medical Technology Co., Ltd. was held on June 17, 2025, with all three supervisors present, complying with relevant laws and regulations [1]. Resolutions Passed - The Supervisory Board approved the proposal to grant restricted stock to three eligible incentive objects under the 2025 Restricted Stock Incentive Plan at a price of 46.16 yuan per share, totaling 16,089 shares [1][2]. - The Supervisory Board approved the proposal to postpone certain fundraising investment projects, stating that the decision was made based on the actual construction situation and did not harm shareholders' interests [2]. - The Supervisory Board approved the use of self-owned foreign exchange funds to pay for the required funds for fundraising projects, with a plan to replace the amount with raised funds, ensuring compliance with relevant regulations and improving fund utilization efficiency [3].